Nanotherapeutics: New Challenges for Safety and Cost-Effectiveness Regulation in Australia
Thomas Alured Faunce
Australian Research Council; Australian National University
February 19, 2007
Medical Journal of Australia, Vol. 186, No. 4, pp. 189-191, 2007
• Nanotechnology is a revolutionary field of micro-manufacturing involving manipulation, by chemical or physical processes, of individual atoms and molecules.
• Pharmaceutical and medical device manufacturers, both in Australia and internationally, have significant investments in nanotechnology research and development.
• It is important that safety regulation of nanotherapeutics keep pace with this growing level of industry interest. A recent senate inquiry recommended the establishment of a working
party, including representatives of the Therapeutic Goods Administration, to consider whether bulk materials classified as safe should be routinely reassessed for use at the
nanoscale level by a permanent, distinct nanotechnology regulator.
• Safety regulation of nanotherapeutics may present unique risk assessment challenges, given the novelty and variety of products, high mobility and reactivity of engineered nanoparticles, and blurring of the diagnostic and therapeutic classifications of “medicines” and “medical devices”.
• Nanotherapeutics is likely to make increasing claims on a particular area of Australian health care regulatory strength: scientific cost-effectiveness assessment of innovation in
• Any review of Australian regulation of nanotechnology should include a critical analysis of both safety issues and cost-effectiveness assessment systems for nanotherapeutics.
Number of Pages in PDF File: 3
Keywords: Nanotechnology, nanomedicine, safety, cost-effectiveness, pharmaceutical regulationAccepted Paper Series
Date posted: May 23, 2009
© 2013 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo1 in 1.313 seconds